SCO-267 is under development for the treatment of non-alcoholic steatohepatitis (NASH), diabetes, nonalcoholic fatty liver disease and obesity. It acts by targeting GPR40. It is administered through ...
Scohia Pharma (Scohia) is a drug discovery company that discovers and develops novel therapies for lifestyle-related diseases including cardiovascular, metabolic, and renal disease. It conducts ...
Background: Nephrotic syndrome (NS) is a prevalent kidney disease in children. Acute kidney injury (AKI) is a severe complication of NS and has the potential to be life-threatening. Objective: The aim ...
Nephrotic syndrome (NS) represents a prevalent syndrome among various chronic kidney disease pathologies and is known for its higher severity and worse prognosis compared with chronic ...